Raxibacumab

Chemical Nameraxibacumab
Dosage FormInjection (intravenous; 1700 mg/34 mL (50 mg/mL)
Drug ClassMonoclonal antibodies
SystemRespiratory
CompanyGlaxoSmithKline
Approval Year2012

Indication

  • For the treatment of adult and pediatric patients with inhalational anthrax due to bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate
Last updated on 4/10/2022

More on this drug: Clinical Trials

Document TitleYearSource
Raxibacumab (raxibacumab) Prescribing Information.2012GlaxoSmithKline, Research Triangle Park, NC

Have we missed a study, or would you like to comment on a study?